<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40267303</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Clinical characteristics and cytokine gene expression in patients with post-COVID-19 syndrome].</ArticleTitle><Pagination><StartPage>e6275</StartPage><MedlinePgn>e6275</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6275</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.14200098</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Post-COVID-19 syndrome occurs 3 months after COVID-19 infection and lasts at least 2 months. There is insufficient information on the genes associated with immune system dysregulation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate gene expression and its relationship with post-COVID-19 syndrome.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Cross-sectional, retrolective and analytical study which included 56 patients with post-COVID-19 syndrome. Clinical characteristics were recorded and serotonin IL-4, IL-1&#x3b2;, SOCS3, ILF13, and IFNL4 genes were analyzed with TRIzol&#xae; Reagent and PCR-RT techniques.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The prevalence of post-COVID-19 syndrome was 82.1%, with no differences in relation to the severity of symptoms or comorbidities. The clinical characteristics related to the presence of the syndrome were female sex with an odds ratio (OR) of 4.25 (95% confidence interval [95% CI] 1.02-17.69), and drug consumption with an OR of 8.25 (95% CI 0.97-70.50). Protective factors for fatigue were serotonin expression with an OR of 0.238 (95% CI 0.060-0.949); for concentration problems, SOCS3 with an OR of 0.188 (95% CI 0.037-0.946), and for memory impairment the IFNL4 with an OR of 0.094 (95% CI 0.015-0.586).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The associated factors with post-COVID-19 syndrome were female sex, drug use, and gene dysregulation of serotonin, INFL4 and SOCS3.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valencia-Guti&#xe9;rrez</LastName><ForeName>Mar&#xed;a Magdalena</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-6894-8402</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, &#xd3;rgano de Operaci&#xf3;n Administrativa Desconcentrada Michoac&#xe1;n, Hospital General de Zona No. 83, Servicio de Urgencias. Morelia, Michoac&#xe1;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-L&#xf3;pez</LastName><ForeName>Modesto</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0355-9195</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Escuela Superior de Medicina, &#xc1;rea de Posgrado Biolog&#xed;a Molecular del Proceso Inflamatorio. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Vielma</LastName><ForeName>Nadia Mabel</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0001-9691-9035</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Centro Interdisciplinario de Ciencias de la Salud-Unidad Santo Tom&#xe1;s, &#xc1;rea de Posgrado. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe1;zaro-Aguilar</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0007-6715-8303</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Centro Interdisciplinario de Ciencias de la Salud-Unidad Santo Tom&#xe1;s, &#xc1;rea de Posgrado. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilera-Sosa</LastName><ForeName>V&#xed;ctor Ricardo</ForeName><Initials>VR</Initials><Identifier Source="ORCID">0000-0002-0636-5567</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Centro Interdisciplinario de Ciencias de la Salud-Unidad Santo Tom&#xe1;s, &#xc1;rea de Posgrado. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas cl&#xed;nicas y expresi&#xf3;n g&#xe9;nica de citocinas en pacientes con s&#xed;ndrome post-COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071223">Suppressor of Cytokine Signaling 3 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="Y">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071223" MajorTopicYN="N">Suppressor of Cytokine Signaling 3 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">el s&#xed;ndrome post-COVID-19 ocurre 3 meses despu&#xe9;s de la infecci&#xf3;n por COVID-19 y tiene una duraci&#xf3;n m&#xed;nima de 2 meses. Hay poca informaci&#xf3;n sobre los genes que se encuentran asociados a la desregulaci&#xf3;n del sistema inmune.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">evaluar la expresi&#xf3;n g&#xe9;nica y su relaci&#xf3;n con el s&#xed;ndrome post-COVID-19.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio transversal, retrolectivo y anal&#xed;tico que incluy&#xf3; 56 pacientes con s&#xed;ndrome post-COVID-19. Se registraron las caracter&#xed;sticas cl&#xed;nicas y se analizaron los genes serotonina IL-4, IL-1&#x3b2;, SOCS3, ILF13, e IFNL4 con t&#xe9;cnicas de TRIzol&#xae; Reagent y t&#xe9;cnica PCR-RT.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">la prevalencia de s&#xed;ndrome post-COVID-19 fue 82.1%, sin diferencias en relaci&#xf3;n con la severidad de los s&#xed;ntomas o comorbilidades. Las caracter&#xed;sticas cl&#xed;nicas relacionadas con la presencia del s&#xed;ndrome fueron: sexo mujer, con una raz&#xf3;n de momios (RM) de 4.25 (intervalo de confianza [IC 95%] 1.02-17.69) y el consumo de f&#xe1;rmacos con RM 8.25 (IC 95% 0.97-70.50). Los factores protectores para fatiga fueron la expresi&#xf3;n de serotonina, con una RM 0.238 (0.060-0.949); para problemas en la concentraci&#xf3;n, la SOCS3 con una RM de 0.188 (0.037-0.946), y para alteraciones en la memoria, el IFNL4 con una RM de 0.094 (0.015-0.586).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">los factores asociados a s&#xed;ndrome post-COVID-19 fueron sexo femenino, consumo de f&#xe1;rmacos y desregulaci&#xf3;n g&#xe9;nica de serotonina, IFNL4 y SOCS3.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2025 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interleukin-13</Keyword><Keyword MajorTopicYN="N">Post-Acute COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">SOCS3 Protein</Keyword><Keyword MajorTopicYN="N">Serotonin</Keyword><Keyword MajorTopicYN="N">interleukin-1beta</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno relacionado con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>23</Day><Hour>15</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40267303</ArticleId><ArticleId IdType="pmc">PMC12080597</ArticleId><ArticleId IdType="doi">10.5281/zenodo.14200098</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO COVID-19 Dashboard. Geneva, Switzerland: WHO; 2024.  Disponible en: https://data.who.int/dashboards/covid19/deaths?n= </Citation></Reference><Reference><Citation>World Health Organization. Post-COVID-19 Conditions. Geneva, Switzerland: WHO; 2024.  Disponible en: https://www.who.int/teams/health-care-readiness/post-covid-19-condition#:~:text=Common%20symptoms%20include%20fatigue%2C%20shortness,persist%20from%20the%20initial%20illness .</Citation></Reference><Reference><Citation>Najafi MB, Javanmard SH. Post-COVID-19 Syndrome Mechanisms, Prevention and Management. Int J Prev Med. 2023 May 24;14:59. doi: 10.4103/ijpvm.ijpvm_508_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijpvm.ijpvm_508_21</ArticleId><ArticleId IdType="pmc">PMC10284243</ArticleId><ArticleId IdType="pubmed">37351054</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. UK Office for National Statistics; 2020. Dec 16,  Disponible en: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongCOVIDsymptomsandCOVID19complications .</Citation></Reference><Reference><Citation>Nalbandian A, Desai AD, Wan EY. Post-COVID-19 Condition. Annu Rev Med. 2023;74:55&#x2013;64. doi: 10.1146/annurev-med-043021-030635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-043021-030635</ArticleId><ArticleId IdType="pubmed">35914765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellai M, O'Keefe JB. Characterization of Prolonged COVID-19 Symptoms in an Outpatient Telemedicine Clinic. Open Forum Infect Dis. 2020;7(10):ofaa420. doi: 10.1093/ofid/ofaa420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa420</ArticleId><ArticleId IdType="pmc">PMC7543492</ArticleId><ArticleId IdType="pubmed">33117851</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: A review. J R Soc Med. 2021;114:428&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3(6):100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol. 2008 Aug;19(4):414&#x2013;422. doi: 10.1016/j.semcdb.2008.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2008.07.010</ArticleId><ArticleId IdType="pmc">PMC2597703</ArticleId><ArticleId IdType="pubmed">18708154</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A, Nemati M, Jafarzadeh S. Contribution of STAT3 to the pathogenesis of COVID-19. Microb Pathog. 2021;154:104836. doi: 10.1016/j.micpath.2021.104836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104836</ArticleId><ArticleId IdType="pmc">PMC7937040</ArticleId><ArticleId IdType="pubmed">33691172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito B, Broggi A, Pandolfi L, et al. Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients. bioRxiv. 2021 Mar 30;:2021.03.30.437173. doi: 10.1101/2021.03.30.437173. Update in: Cell. 2021 Sep 16;184(19):4953-4968.e16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.30.437173</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong MC, Huang J, Wong YY, et al. Epidemiology, Symptomatology, and Risk Factors for Long COVID Symptoms: Population-Based, Multicenter Study. JMIR Public Health Surveill. 2023;9:e42315. doi: 10.2196/42315.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/42315</ArticleId><ArticleId IdType="pmc">PMC9994465</ArticleId><ArticleId IdType="pubmed">36645453</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller SA, Isaaka L, Mumm R, et al. Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health. 2023;11(11):e1713&#x2013;e1724. doi: 10.1016/S2214-109X(23)00384-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(23)00384-4</ArticleId><ArticleId IdType="pubmed">37858583</ArticleId></ArticleIdList></Reference><Reference><Citation>Coste J, Tebeka S, Decio V, et al. Prevalence of post-COVID-19 condition in the French general population after the first epidemic waves. Infect Dis Now. 2023;53(1):104631. doi: 10.1016/j.idnow.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9642032</ArticleId><ArticleId IdType="pubmed">36368627</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, et al. COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. J Am Med Assoc. 2020;324:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Hermosillo JA, Mart&#xed;nez-L&#xf3;pez JP, Carrillo-Lamp&#xf3;n SA, et al. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain Sci. 2021;11(6):760. doi: 10.3390/brainsci11060760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11060760</ArticleId><ArticleId IdType="pmc">PMC8227652</ArticleId><ArticleId IdType="pubmed">34201087</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhafiz AS, Ali A, Maaly AM, et al. Predictors of post-COVID symptoms in Egyptian patients: Drugs used in COVID-19 treatment are incriminated. PLoS One. 2022;17(3):e0266175. doi: 10.1371/journal.pone.0266175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266175</ArticleId><ArticleId IdType="pmc">PMC8970499</ArticleId><ArticleId IdType="pubmed">35358268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac13635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac13635</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186(22):4851&#x2013;4867. doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahani RH, Ajam A, Naeini AR. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2023;23(1):197. doi: 10.1186/s12879-023-08172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08172-5</ArticleId><ArticleId IdType="pmc">PMC10064948</ArticleId><ArticleId IdType="pubmed">37003990</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz de Paula CB, de Azevedo MLV, Nagashima S, et al. IL-4/IL-13 remodeling pathway of COVID-19 lung injury. Sci Rep. 2020;10(1):18689. doi: 10.1038/s41598-020-75659-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75659-5</ArticleId><ArticleId IdType="pmc">PMC7596721</ArticleId><ArticleId IdType="pubmed">33122784</ArticleId></ArticleIdList></Reference><Reference><Citation>Modher Nabat Al-Ajrash A, Mohammed Ali SH, Al-Bayaa YJ, et al. Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection. Arch Razi Inst. 2022 Dec 31;77(6):2291&#x2013;2298. doi: 10.22092/ARI.2022.358616.2266.</Citation><ArticleIdList><ArticleId IdType="doi">10.22092/ARI.2022.358616.2266</ArticleId><ArticleId IdType="pmc">PMC10237548</ArticleId><ArticleId IdType="pubmed">37274898</ArticleId></ArticleIdList></Reference><Reference><Citation>Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. medRxiv. 2021:2020.06.18.20134353. doi: 10.1101/2020.06.18.20134353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.18.20134353</ArticleId><ArticleId IdType="pmc">PMC8410056</ArticleId><ArticleId IdType="pubmed">34185704</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Worlock KB, Huang N, et al. Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature. 2022;602(7896):321&#x2013;327. doi: 10.1038/s41586-021-04345-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04345-x</ArticleId><ArticleId IdType="pmc">PMC8828466</ArticleId><ArticleId IdType="pubmed">34937051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Rajagopalan D, Gamage AM, et al. Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity. Nat Commun. 2024;15(1):567. doi: 10.1038/s41467-023-44524-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44524-0</ArticleId><ArticleId IdType="pmc">PMC10796319</ArticleId><ArticleId IdType="pubmed">38238298</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Han J, Cui R, et al. The Promotion of Humoral Immune Responses in Humans via SOCS1-Mediated Th2-Bias Following SARS-CoV-2 Vaccination. Vaccines (Basel) 2023;11(11):1730. doi: 10.3390/vaccines11111730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111730</ArticleId><ArticleId IdType="pmc">PMC10674672</ArticleId><ArticleId IdType="pubmed">38006062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39527813</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Epidemiological characteristics in gastroenteritis diagnosis before and during the pandemic].</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>5</EndPage><MedlinePgn>1-5</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e5710</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.10998692</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The end of the global sanitary emergency derived from the COVID-19 pandemic was declared by WHO in May 2022. In this sanitary emergency, massive campaigns promoting hygiene and social distancing measures were displayed, which may have not only helped to ease the spread of respiratory infections, but also of gastroenteritis of presumably infectious origin (GPIO).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To estimate the change in prevalence of GPIO in the first level of attention between a pre-pandemic period and during the COVID-19 pandemic.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Retrospective, observational, cross-sectional, and comparative study which included all patients who looked for medical attention in a first-level center in 2 periods: pre-pandemic (2018-2019) and during pandemic (2020-2021). Data was retrieved from electronic medical records. It was carried out a descriptive analysis with frequencies and percentages, and Fisher's exact test was used to calculate the prevalence of GPIO.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During the pre-pandemic a total of 620,164 consultations occurred and 497,750 in the pandemic period. Prevalence of GPIO in the first period was 1.32% (n = 8207) and 0.42% (n = 2132) in the second period (p &lt; 0.001). No significant changes in symptomatology were observed, except for change in consistency in feces (p = 0.001) and vomiting (p = 0.01). Hand hygiene education was reported in 5.2% of the cases in the first period, and in 19.2% in the second period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">There was a significant reduction in the prevalence of GPIO during the pandemic period, probably due to the massive hygienic measures displayed to mitigate the spread of COVID-19.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2024 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Salinas</LastName><ForeName>Claudia Marcela</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0009-0003-5735-4520</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 7, Departamento de Medicina Familiar. San Pedro Garza Garc&#xed;a, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaquera-Alfaro</LastName><ForeName>H&#xe9;ctor Alejandro</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0001-9657-9130</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Medicina, Centro de An&#xe1;lisis Avanzado de Informaci&#xf3;n Cient&#xed;fica 360. Monterrey, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez-Villalobos</LastName><ForeName>Neri Alejandro</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0001-5208-1429</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 7, Departamento de Medicina Familiar. San Pedro Garza Garc&#xed;a, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Hern&#xe1;ndez</LastName><ForeName>Fernando Gerardo</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0003-4912-180X</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Medicina, Centro de Desarrollo de Investigaci&#xf3;n 360. Monterrey, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Hern&#xe1;ndez</LastName><ForeName>Rosa Margarita</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0009-0005-0163-5926</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 7, Departamento de Medicina Familiar. San Pedro Garza Garc&#xed;a, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez-S&#xe1;nchez</LastName><ForeName>Erika Renata</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0001-5837-5209</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 7, Departamento de Medicina Familiar. San Pedro Garza Garc&#xed;a, Nuevo Le&#xf3;n, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas epidemiol&#xf3;gicas en el diagn&#xf3;stico de gastroenteritis antes y durante la pandemia.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="Y">Gastroenteritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">la OMS declar&#xf3; el fin de la emergencia sanitaria de la pandemia por COVID-19 en mayo de 2022. En ella se desplegaron campa&#xf1;as masivas que promov&#xed;an medidas de higiene que pueden no solo haber ayudado a frenar la propagaci&#xf3;n de infecciones respiratorias, sino tambi&#xe9;n de gastroenteritis de origen presuntamente infeccioso (GOPI).</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="UNASSIGNED">estimar el cambio en la prevalencia de GOPI en el primer nivel de atenci&#xf3;n entre un periodo previo y durante la pandemia de COVID-19.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio retrospectivo, observacional, transversal y comparativo que incluy&#xf3; a todos los pacientes que buscaron atenci&#xf3;n m&#xe9;dica en un centro de primer nivel en 2 periodos: prepandemia (2018-2019) y durante la pandemia (2020-2021). Los datos se obtuvieron de los expedientes m&#xe9;dicos electr&#xf3;nicos. Se hizo un an&#xe1;lisis descriptivo con frecuencias y porcentajes, y se us&#xf3; la prueba exacta de Fisher para calcular diferencias en la prevalencia de GOPI.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">durante la prepandemia se realizaron 620,164 consultas y 497,750 en la pandemia. La prevalencia de GOPI en el primer periodo fue 1.32% (n = 8207) y 0.42% (n = 2132) en el segundo (p &lt; 0.001). No hubo cambios significativos en la sintomatolog&#xed;a, salvo en el cambio en la consistencia de las heces (p = 0.001) y el v&#xf3;mito (p = 0.01). La educaci&#xf3;n sobre higiene de manos se inform&#xf3; en el 5.2% de los casos en el primer periodo y 19.2% en el segundo.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">la prevalencia de GOPI se redujo significativamente en el periodo de pandemia, quiz&#xe1;s debido a las medidas de higiene masiva implementadas para mitigar la propagaci&#xf3;n de la COVID-19.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2024 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gastroenteritis</Keyword><Keyword MajorTopicYN="N">Hand Disinfection</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>17</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>14</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>11</Day><Hour>16</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39527813</ArticleId><ArticleId IdType="pmc">PMC12185049</ArticleId><ArticleId IdType="doi">10.5281/zenodo.10998692</ArticleId><ArticleId IdType="pii">e5710</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64(11):832&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234945</ArticleId><ArticleId IdType="pubmed">30429181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Graci&#xe1;n HL, Ponce-Rosas ER, Madrigal-de Le&#xf3;n HG, et al. An&#xe1;lisis de los motivos de consulta para la toma de decisiones en Medicina Familiar. Aten Fam. 2015;22(1):14&#x2013;18. doi: 10.1016/S1405-8871(16)30039-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1405-8871(16)30039-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Estrada G, Moreno-Altamirano L, Pahua D&#xed;az D, et al. Panorama epidemiol&#xf3;gico de M&#xe9;xico, principales causas de morbilidad y mortalidad. Rev Fac Med UNAM. 2016;59(6):8&#x2013;22.</Citation></Reference><Reference><Citation>Palacio-Mej&#xed;a LS, Rojas-Botero M, Molina-V&#xe9;lez D, et al. Overview of acute diarrheal disease at the dawn of the 21st century: The case of Mexico. Salud Publica Mex. 2020;62(1):14&#x2013;24. doi: 10.21149/9954.</Citation><ArticleIdList><ArticleId IdType="doi">10.21149/9954</ArticleId><ArticleId IdType="pubmed">31314211</ArticleId></ArticleIdList></Reference><Reference><Citation>Olaiz-Fern&#xe1;ndez GA, G&#xf3;mez-Pe&#xf1;a EG, Ju&#xe1;rez-Flores A, et al. Panorama hist&#xf3;rico de la enfermedad diarreica aguda en M&#xe9;xico y el futuro de su prevenci&#xf3;n. Salud Publica Mex. 2020;62(1):25&#x2013;35. doi: 10.21149/10002.</Citation><ArticleIdList><ArticleId IdType="doi">10.21149/10002</ArticleId><ArticleId IdType="pubmed">31869558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arellanos-Soto D, Padilla-Rivas G, Ramos-Jimenez J, et al. Decline in influenza cases in Mexico after the implementation of public health measures for COVID-19. Sci Rep. 2021;11(1):10730. doi: 10.1038/s41598-021-90329-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90329-w</ArticleId><ArticleId IdType="pmc">PMC8144183</ArticleId><ArticleId IdType="pubmed">34031515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023;21(3):195&#x2013;210. doi: 10.1038/s41579-022-00807-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00807-9</ArticleId><ArticleId IdType="pmc">PMC9574826</ArticleId><ArticleId IdType="pubmed">36253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves HE, Pich&#xe9;-Renaud PP, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. Lancet Reg Health - Am. 2021;1:100015. doi: 10.1016/j.lana.2021.100015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100015</ArticleId><ArticleId IdType="pmc">PMC8285668</ArticleId><ArticleId IdType="pubmed">34386788</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello AE, Coulborn RM, Perez V, et al. Effect of Hand Hygiene on Infectious Disease Risk in the Community Setting: A Meta-Analysis. Am J Public Health. 2008;98(8):1372&#x2013;1381. doi: 10.2105/AJPH.2007.124610.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.124610</ArticleId><ArticleId IdType="pmc">PMC2446461</ArticleId><ArticleId IdType="pubmed">18556606</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckardt AJ, Baumgart DC. Viral Gastroenteritis in Adults. Recent Patents Anti-Infect Drug Disc. 2011;6(1):54&#x2013;63. doi: 10.2174/157489111794407877.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157489111794407877</ArticleId><ArticleId IdType="pubmed">21210762</ArticleId></ArticleIdList></Reference><Reference><Citation>Armistead I, Tran A, White AE, et al. Trends in Outpatient Medical-Care Seeking for Acute Gastroenteritis During the COVID-19 Pandemic, 2020. Foodborne Pathog Dis. 2022;19(4):290&#x2013;292. doi: 10.1089/fpd.2021.0099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/fpd.2021.0099</ArticleId><ArticleId IdType="pubmed">35020464</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer T, Benson LS, Porucznik C, et al. Impact of COVID-19 Social Distancing Mandates on Gastrointestinal Pathogen Positivity: Secondary Data Analysis. JMIR Public Health Surveill. 2022;8(8):e34757. doi: 10.2196/34757.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/34757</ArticleId><ArticleId IdType="pmc">PMC9407155</ArticleId><ArticleId IdType="pubmed">35507923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray LC, Collins JP, Griffin PM, et al. Decreased Incidence of Infections Caused by Pathogens Transmitted Commonly Through Food During the COVID-19 Pandemic &#x2014; Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2017-2020. MMWR Morb Mortal Wkly Rep. 2021;70(38):1332&#x2013;1336. doi: 10.15585/mmwr.mm7038a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7038a4</ArticleId><ArticleId IdType="pmc">PMC8459900</ArticleId><ArticleId IdType="pubmed">34555002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetteh-Quarcoo PB, Afutu E, Wiafe-Ansong M, et al. Contrasting Hygiene-Related Gastrointestinal Infections and Stress-Related Diseases at a Primary Health Care Facility within a Sub-Saharan African City: Before and during the COVID-19 Pandemic. Diseases. 2023;11(1):2. doi: 10.3390/diseases11010002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases11010002</ArticleId><ArticleId IdType="pmc">PMC9844452</ArticleId><ArticleId IdType="pubmed">36648867</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbakaya BC, Lee PH, Lee RLT. Hand Hygiene Intervention Strategies to Reduce Diarrhoea and Respiratory Infections among Schoolchildren in Developing Countries: A Systematic Review. Int J Environ Res Public Health. 2017;14(4):371. doi: 10.3390/ijerph14040371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph14040371</ArticleId><ArticleId IdType="pmc">PMC5409572</ArticleId><ArticleId IdType="pubmed">28368323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuitunen I, Artama M, M&#xe4;kel&#xe4; L, et al. Effect of Social Distancing Due to the COVID-19 Pandemic on the Incidence of Viral Respiratory Tract Infections in Children in Finland During Early 2020. Pediatr Infect Dis J. 2020;39(12):e423. doi: 10.1097/INF.0000000000002845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002845</ArticleId><ArticleId IdType="pubmed">32773660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu NC, Chi H, Tai YL, et al. Impact of Wearing Masks, Hand Hygiene, and Social Distancing on Influenza, Enterovirus, and All-Cause Pneumonia During the Coronavirus Pandemic: Retrospective National Epidemiological Surveillance Study. J Med Internet Res. 2020;22(8):e21257. doi: 10.2196/21257.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/21257</ArticleId><ArticleId IdType="pmc">PMC7471891</ArticleId><ArticleId IdType="pubmed">32750008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39106519</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Epidemiological, clinical, and biochemical characteristics of patients in the LUPUS-IMMex cohort].</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>6</EndPage><MedlinePgn>1-6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e5247</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.10278103</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and body systems.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To describe the sociodemographic, clinical, and biochemical characteristics of the Lupus-IMMS-Mexico (LUPUS-IMMex) patient cohort from a tertiary-level center.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Observational descriptive study of 160 patients with diagnosis of SLE belonging to the aforementioned cohort. Various variables were analyzed at the time of diagnosis. For quantitative variables, normality tests were applied, followed by measures of central tendency and dispersion according to their distribution. For categorical variables, frequencies and percentages were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">81.87% of the patients were female, with a median age at diagnosis of 28 years. 18.12% had a family history of SLE, and concurrently with SLE, 32.50% had hypertension, and 11.25% had antiphospholipid syndrome. The most common clinical manifestation was joint involvement (68.12%), renal (49.37%) and hematological (43.75%) manifestations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">SLE affects millions globally. Lack of awareness leads to delayed diagnoses, suboptimal management, and diminished quality of life. After analyzing 160 patients with SLE, their clinical, socioeconomic, and therapeutic characteristics are largely like other cohorts, with differences attributable to ethnic and geographical influences. Informing patients about SLE and providing reliable resources are essential for self-care. Awareness promotes research, therapies, and enhances medical care and the lives of patients globally.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2024 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ocampo-Torres</LastName><ForeName>Mario Cesar</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-5414-0346</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bravo-Rojas</LastName><ForeName>Francisco Martin</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0002-6527-6476</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Unidad de Investigaci&#xf3;n M&#xe9;dica en Enfermedades Nefrol&#xf3;gicas. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Badajoz</LastName><ForeName>Aida</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0006-2901-0888</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Unidad de Investigaci&#xf3;n M&#xe9;dica en Enfermedades Nefrol&#xf3;gicas. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-V&#xe1;squez</LastName><ForeName>Ramiro</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5270-2974</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-P&#xe9;rez</LastName><ForeName>Astrid Asminda</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0001-5537-2897</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camargo-Coronel</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-5630-9728</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez-Zaragoza</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><Identifier Source="ORCID">0000-0002-0093-2778</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna-Pe&#xf1;a</LastName><ForeName>Eleonor</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0007-7229-6954</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Unidad de Investigaci&#xf3;n M&#xe9;dica en Enfermedades Nefrol&#xf3;gicas. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazos-P&#xe9;rez</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6791-4147</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Servicio de Nefrolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Rivera</LastName><ForeName>Juan Carlos H</ForeName><Initials>JCH</Initials><Identifier Source="ORCID">0000-0002-4038-5756</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Unidad de Investigaci&#xf3;n M&#xe9;dica en Enfermedades Nefrol&#xf3;gicas. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas epidemiol&#xf3;gicas, cl&#xed;nicas y bioqu&#xed;micas de los pacientes en la cohorte LUPUS-IMMex.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">el lupus eritematoso sist&#xe9;mico (LES) es una enfermedad autoinmunitaria cr&#xf3;nica que puede afectar a m&#xfa;ltiples &#xf3;rganos y sistemas del cuerpo.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">describir las caracter&#xed;sticas sociodemogr&#xe1;ficas, cl&#xed;nicas y bioqu&#xed;micas de la cohorte de pacientes Lupus-IMMS-M&#xe9;xico (LUPUS-IMMex) de un hospital de tercer nivel.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio descriptivo observacional de 160 pacientes con diagn&#xf3;stico de LES de la cohorte mencionada. Se analizaron diversas variables al momento del diagn&#xf3;stico. Para variables cuantitativas se aplicaron pruebas de normalidad y posteriormente medidas de tendencia central y dispersi&#xf3;n de acuerdo con su distribuci&#xf3;n. Para variables categ&#xf3;ricas se calcularon frecuencias y porcentajes.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">81.87% de los pacientes fueron del sexo femenino, con mediana de edad al diagn&#xf3;stico de 28 a&#xf1;os. El 18.12% ten&#xed;an antecedentes familiares de LES y concomitante al LES, hipertensi&#xf3;n (32.50%) y s&#xed;ndromes antifosfol&#xed;pidos (11.25%). Las afecciones cl&#xed;nicas m&#xe1;s frecuentes fueron la articular (68.12%), la renal (49.37%) y la hematol&#xf3;gica (43.75%).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">el LES afecta a millones de personas globalmente. La falta de conciencia lleva a diagn&#xf3;sticos tard&#xed;os, manejo deficiente y baja calidad de vida. Tras analizar 160 pacientes con LES, sus caracter&#xed;sticas cl&#xed;nicas, socioecon&#xf3;micas y terap&#xe9;uticas son mayormente similares a otras cohortes, con diferencias atribuibles a influencias &#xe9;tnicas y geogr&#xe1;ficas. Informar a los pacientes sobre el LES y brindar recursos confiables es esencial para el autocuidado. La sensibilizaci&#xf3;n fomenta la investigaci&#xf3;n, las terapias y mejora la atenci&#xf3;n m&#xe9;dica y la vida de pacientes a nivel global.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2024 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">Rheumatic Diseases</Keyword><Keyword MajorTopicYN="N">Statistics</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>17</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39106519</ArticleId><ArticleId IdType="pmc">PMC12094797</ArticleId><ArticleId IdType="doi">10.5281/zenodo.10278103</ArticleId><ArticleId IdType="pii">e5247</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344&#x2013;2358. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Parton H, Wang L, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta&#x2010;Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991&#x2013;996. doi: 10.1002/art.41632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41632</ArticleId><ArticleId IdType="pmc">PMC8169527</ArticleId><ArticleId IdType="pubmed">33474834</ArticleId></ArticleIdList></Reference><Reference><Citation>Xibill&#xe9; D, P&#xe9;rez M, Carrillo S, et al. Gu&#xed;a de pr&#xe1;ctica cl&#xed;nica para el manejo del lupus eritematoso sist&#xe9;mico propuesta por el Colegio Mexicano de Reumatolog&#xed;a. Reumatol Clin. 2019;15(1):3&#x2013;20. doi: 10.1016/j.reuma.2018.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2018.03.011</ArticleId><ArticleId IdType="pubmed">29735288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe1;ez-Ballestas I, Sanin LH, Moreno-Montoya J, et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011;86:3&#x2013;8. doi: 10.3899/jrheum.100951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100951</ArticleId><ArticleId IdType="pubmed">21196592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernder A, Richter JG, Fischer-Betz R, et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. Lupus. 2021;30(3):431&#x2013;438. doi: 10.1177/0961203320983445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320983445</ArticleId><ArticleId IdType="pmc">PMC7933718</ArticleId><ArticleId IdType="pubmed">33402036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070928</ArticleId><ArticleId IdType="pmc">PMC8301935</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi D, Elefante E, Schilir&#xf2; D, et al. One year in review 2022: systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):4&#x2013;14. doi: 10.55563/clinexprheumatol/nolysy.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/nolysy</ArticleId><ArticleId IdType="pubmed">35088691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172(11):ITC81&#x2013;ITC96. doi: 10.7326/AITC202006020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332&#x2013;2343. doi: 10.1016/S0140-6736(19)30237-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra L, Barba PJ, Morgado D. FR-Criterios de clasificaci&#xf3;n 2019 del lupus eritematoso sist&#xe9;mico. Actas Dermo-Sifiliogr&#xe1;ficas. 2022;113(3):310&#x2013;312. doi: 10.1016/j.ad.2020.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ad.2020.04.021</ArticleId><ArticleId IdType="pubmed">35526925</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, Calvo-Al&#xe9;n J, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 2006;65(9):1168&#x2013;1174. doi: 10.1136/ard.200X.046896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.200X.046896</ArticleId><ArticleId IdType="pmc">PMC1798273</ArticleId><ArticleId IdType="pubmed">16905579</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons BA, Catoggio LJ, Cardiel MH, et al. The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity among &#x201c;Hispanics&#x201d;. Medicine (Baltimore) 2004;83(1):1&#x2013;17. doi: 10.1097/01.md.0000104742.42401.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000104742.42401.e2</ArticleId><ArticleId IdType="pubmed">14747764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamijoyo L, Candrianita S, Rahmadi AR, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. Lupus. 2019;28(13):1604&#x2013;1609. doi: 10.1177/0961203319878499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319878499</ArticleId><ArticleId IdType="pubmed">31566078</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Lu G, Clifton SC, et al. Influence of Socio-Demographic Factors in Patients With Cutaneous Lupus Erythematosus. Front Med. 2022;9:916134. doi: 10.3389/fmed.2022.916134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.916134</ArticleId><ArticleId IdType="pmc">PMC9311297</ArticleId><ArticleId IdType="pubmed">35899206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi J, Segura BT, Wincup C, Rahman A. Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Clin Rev Allergy Immunol. 2018;55(3):352&#x2013;367. doi: 10.1007/s12016-017-8640-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8640-5</ArticleId><ArticleId IdType="pmc">PMC6244922</ArticleId><ArticleId IdType="pubmed">28853005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez A, Hani Butrus F, Johansson P, et al. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology. 2021;60(3):1260&#x2013;1272. doi: 10.1093/rheumatology/keaa453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa453</ArticleId><ArticleId IdType="pmc">PMC7937019</ArticleId><ArticleId IdType="pubmed">32918459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono M, Nagafuchi Y, Shoda H, et al. The Impact of Obesity and a High-Fat Diet on Clinical and Immunological Features in Systemic Lupus Erythematosus. Nutrients. 2021;13(2):504. doi: 10.3390/nu13020504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020504</ArticleId><ArticleId IdType="pmc">PMC7913625</ArticleId><ArticleId IdType="pubmed">33557015</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldea-V&#xe1;squez KL.  Calidad de vida y autoestima en pacientes con lupus eritematosos sist&#xe9;mico en Hospital Regional Lambayeque y Almanzor Aguinaga Asenjo 2017. Repositorio Acad&#xe9;mico de la Universidad de San Mart&#xed;n de Porres; Chiclayo, Per&#xfa;: 2019.  Disponible en: https://repositorio.usmp.edu.pe/bitstream/handle/20.500.12727/4445/aldea_vkl.pdf?sequence=3&amp;isAllowed=y .</Citation></Reference><Reference><Citation>Salmasi S, Sayre EC, Avi&#xf1;a JA, et al. Adherence to Antimalarial Therapy and Risk of Type 2 Diabetes Mellitus Among Patients With Systemic Lupus Erythematosus: A Population&#x2010;Based Study. Arthritis Care Res. 2021;73(5):702&#x2013;706. doi: 10.1002/acr.24147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24147</ArticleId><ArticleId IdType="pubmed">31961497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz C, Isenberg DA. Review of major endocrine abnormalities in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37(5):791&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">31172923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni J, Li J, Wang Y, et al. Systemic Lupus Erythematosus Patients With Related Organic Damage Are at High Risk of Hypothyroidism. Front Endocrinol. 2022;13:920283. doi: 10.3389/fendo.2022.920283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.920283</ArticleId><ArticleId IdType="pmc">PMC9335194</ArticleId><ArticleId IdType="pubmed">35909519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M, Gatto M, Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59(Supplement_5):v39&#x2013;v51. doi: 10.1093/rheumatology/keaa381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bootsma H, Spronk P, de Boer G, et al. Prevention of relapses in systemic lupus erythematosus. Lancet. 1995;345(8965):1595&#x2013;1599. doi: 10.1016/s0140-6736(95)90114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(95)90114-0</ArticleId><ArticleId IdType="pubmed">7783536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929&#x2013;939. doi: 10.1056/NEJMra071297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Costenbader KH, Johnson SR, et al. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis Rheumatol. 2019;71(1):91&#x2013;98. doi: 10.1002/art.40674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40674</ArticleId><ArticleId IdType="pubmed">30035365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasoto SG, Adriano MV, Bonfa E. Sj&#xf6;gren's syndrome and systemic lupus erythematosus: links and risks. Open Access Rheumatol. 2019;11:33&#x2013;45. doi: 10.2147/OARRR.S167783.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S167783</ArticleId><ArticleId IdType="pmc">PMC6357904</ArticleId><ArticleId IdType="pubmed">30774485</ArticleId></ArticleIdList></Reference><Reference><Citation>Alani H, Henty JR, Thompson NL, et al Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sj&#xf6;gren's syndrome (secondary Sj&#xf6;gren's syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018;47(2):141&#x2013;154. doi: 10.1080/03009742.2017.1324909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2017.1324909</ArticleId><ArticleId IdType="pubmed">28927315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38016123</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Clinical features of pericarditis in patients with SARS-CoV-2].</ArticleTitle><Pagination><StartPage>S269</StartPage><EndPage>S274</EndPage><MedlinePgn>S269-S274</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">COVID-19 disease (coronavirus disease 2019) has multiple potentially fatal cardiovascular complications and pericarditis is one of them; however, if prompt treatment is given, fatal events associated to this complication decrease. Its frequency and presentation characteristics are unknown, which is why its early diagnosis is important.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To know the frequency of pericarditis secondary to COVID-19 and its presentation characteristics.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Cross-sectional study in patients with a diagnosis of pericarditis after COVID-19 disease (with a positive test). Symptoms, age, sex, comorbidities, and electrocardiogram (ECG) and transthoracic echocardiogram (TTE) results were obtained.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 3364 patients positive for COVID-19 were registered, out of which 10 met criteria for pericarditis, which represented a frequency of 0.30%. The average age of the sample was 46.1 years and 60% predominated in the male gender with a 1.5:1 ratio. The most frequent clinical characteristics were the presence of retrosternal pain (90%), absence of comorbidity (50%), and absence of electrocardiographic changes (40%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Pericarditis has a low frequency in patients with COVID-19. The predominant clinical presentation is chest pain. Almost half will not have electrocardiographic changes, and half will not have comorbidities.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;nez-Mata</LastName><ForeName>Luis Alonso</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0003-3131-2181</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Especialidades No. 1, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledesma-Ram&#xed;rez</LastName><ForeName>Silvia Amparo</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-3505-9286</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Hospital General de Zona con Medicina Familiar No. 3, Servicio de Cardiolog&#xed;a. Salamanca, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Ramos</LastName><ForeName>X&#xf3;chitl</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2161-826X</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, &#xd3;rgano de Operaci&#xf3;n Administrativa Desconcentrada Guanajuato, Coordinaci&#xf3;n Auxiliar M&#xe9;dica de Investigaci&#xf3;n en Salud.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas cl&#xed;nicas de la pericarditis en pacientes con SARS-CoV-2.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">la enfermedad COVID-19 (coronavirus disease 2019) tiene m&#xfa;ltiples complicaciones cardiovasculares potencialmente mortales y la pericarditis es una de ellas; sin embargo, si se da un tratamiento oportuno disminuyen sus eventos fatales. Se desconoce su frecuencia y caracter&#xed;sticas de presentaci&#xf3;n, por lo que es importante su diagn&#xf3;stico temprano.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">conocer la frecuencia de pericarditis secundaria a COVID-19 y sus caracter&#xed;sticas de presentaci&#xf3;n.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio transversal en pacientes con diagn&#xf3;stico de pericarditis posterior a la enfermedad COVID-19 (con prueba positiva). Se obtuvo la sintomatolog&#xed;a, edad, sexo, comorbilidades y resultados de electrocardiograma (ECG) y ecocardiograma transtor&#xe1;cico (ETT).</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">se registraron 3364 pacientes positivos a COVID-19, de los cuales 10 cumplieron con criterios para pericarditis, lo que represent&#xf3; una frecuencia del 0.30%. La edad promedio de la muestra fue de 46.1 a&#xf1;os y predomin&#xf3; en el g&#xe9;nero masculino (60%) con una relaci&#xf3;n 1.5:1. Las caracter&#xed;sticas cl&#xed;nicas m&#xe1;s frecuentes fueron la presencia de dolor retroesternal (90 %), ausencia de comorbilidad (50 %) y ausencia de cambios electrocardiogr&#xe1;ficos (40%).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">la pericarditis tiene una frecuencia baja en pacientes con COVID-19. La presentaci&#xf3;n cl&#xed;nica predominante es el dolor retroesternal. Casi la mitad no tendr&#xe1; cambios electrocardiogr&#xe1;ficos y la mitad no tendr&#xe1; comorbilidades.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular Diseases</Keyword><Keyword MajorTopicYN="N">Coronavirus Infections</Keyword><Keyword MajorTopicYN="N">Cross-Sectional Studies</Keyword><Keyword MajorTopicYN="N">Echocardiography</Keyword><Keyword MajorTopicYN="N">Ecocardiograf&#xed;a</Keyword><Keyword MajorTopicYN="N">Enfermedades Cardiovasculares</Keyword><Keyword MajorTopicYN="N">Estudios Transversales</Keyword><Keyword MajorTopicYN="N">Infecciones por Coronavirus</Keyword><Keyword MajorTopicYN="N">Pericarditis</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>28</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38016123</ArticleId><ArticleId IdType="pmc">PMC11952762</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Inzunza-Cervantes G, Ornelas-Aguirre JM, Trujillo-Garc&#xed;a JJ, Pe&#xf1;a-Valenzuela AN. Para entender el SARS-CoV-2: un an&#xe1;lisis de la pandemia actual. Rev Med Inst Mex Seguro Soc. 2020;58(Supl 2):S164&#x2013;S174. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/3673/4166 .</Citation><ArticleIdList><ArticleId IdType="pubmed">34695329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;a-S&#xe1;nchez P, Monroy-Garc&#xed;a A, Montesinos JJ, Guti&#xe9;rrez-de la Barrera M, Vadillo-Rosado EM, Ch&#xe1;vez-Gonz&#xe1;lez MA, et al.  Biolog&#xed;a del SARS CoV 2: hacia el entendimiento y tratamiento de COVID 19. Rev Med Inst Mex Seguro Soc. 2020;58(Supl 2):S194&#x2013;S214. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/3722/4174 .</Citation><ArticleIdList><ArticleId IdType="pubmed">34695332</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente-Herrera A, S&#xe1;nchez-De la Torre EJ, Enr&#xed;quez-Contreras JM. Manifestaciones cardiol&#xf3;gicas en pacientes con COVID-19. Med Int Mex. 2020 mayo-junio;36(3):357&#x2013;364. doi: 10.24245/mim.v36i3.4229.</Citation><ArticleIdList><ArticleId IdType="doi">10.24245/mim.v36i3.4229</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Ponce de Le&#xf3;n JD, C&#xe1;rdenas-Mar&#xed;n PA, Giraldo-Gonz&#xe1;lez GC, Herrera-Escand&#xf3;n A. Coronavirus &#x2013; COVID 19: M&#xe1;s all&#xe1; de la enfermedad pulmonar, qu&#xe9; es y qu&#xe9; sabemos del v&#xed;nculo con el sistema cardiovascular. Revista Colombiana de Cardiolog&#xed;a. 2020;27(3):142&#x2013;152. doi: 10.1016/j.rccar.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rccar.2020.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagova O, Varionchik N, Zaidenov V, Savina P, Sarkisova N. Anti&#x2010;heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID&#x2010;19. Eur J Immunol. 2021;51(4):893&#x2013;902. doi: 10.1002/eji.202048930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048930</ArticleId><ArticleId IdType="pubmed">33368288</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Mart&#xed;nez FJ, Luna-Montalb&#xe1;n R, Orozco-Ju&#xe1;rez K, Ch&#xe1;vez-L&#xe1;rraga AJ, Velasco-Santos JI, Verazaluce-Rodr&#xed;guez BE. Diferencia sodio-cloro como predictor pron&#xf3;stico en pacientes adultos con diagn&#xf3;stico de COVID-19. Rev Med Inst Mex Seguro Soc. 2022;60(4):440&#x2013;446. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/4547/4415 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10396010</ArticleId><ArticleId IdType="pubmed">35816689</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagrenat C, Sauer F, Jochum G, Uhry S, Heyer H, Keller O, et al. Observational cohort study of pericarditis associated to COVID-19 affection. Archives of Cardiovascular Diseases Supplements. 2021;13(1):165. doi: 10.1016/j.acvdsp.2020.10.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvdsp.2020.10.348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiabrando JG, Bonaventura A, Vecchi&#xe9; A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of Acute and Recurrent Pericarditis. Journal of the American College of Cardiology. 2020;75(1):76&#x2013;92. doi: 10.1016/j.jacc.2019.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.11.021</ArticleId><ArticleId IdType="pubmed">31918837</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrettou AR, Parissis J, Ikonomidis I. The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19) Front Cardiovasc Med. 2020;7:129. doi: 10.3389/fcvm.2020.00129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.00129</ArticleId><ArticleId IdType="pmc">PMC7492803</ArticleId><ArticleId IdType="pubmed">32984405</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Esquivel MA, Huerta-Liceaga F, Mart&#xed;nez-Garz&#xf3;n LA, Sandoval-Espadas RA, Salame-Khouri L. Infarto agudo al miocardio con elevaci&#xf3;n del segmento ST en &#xe9;poca de COVID-19. Rev Med Inst Mex Seguro Soc. 2020;58(Supl 2):S268&#x2013;S281. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/3738/4186 .</Citation><ArticleIdList><ArticleId IdType="pubmed">34695339</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto Mexicano del Seguro Social. Gu&#xed;a de Pr&#xe1;ctica Cl&#xed;nica Diagn&#xf3;stico y tratamiento de pericarditis en el adulto. Gu&#xed;a de Evidencias y Recomendaciones. IMSS; M&#xe9;xico: 2017.  [29 de junio de 2017].  Disponible en: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/463GER.pdf .</Citation></Reference><Reference><Citation>Adler Y, Charron P, Imazio M, Badano L, Bar&#xf3;n-Esquivias G, Bogaert J, et al. Art&#xed;culo especial Gu&#xed;a ESC 2015 sobre el diagn&#xf3;stico y tratamiento de las enfermedades del pericardio. Revista Espa&#xf1;ola de Cardiolog&#xed;a. 2015;68(12):1126&#x2013;e1146. doi: 10.1016/j.recesp.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recesp.2015.10.011</ArticleId><ArticleId IdType="pubmed">26675200</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley BJR, Harrison SL, Fazio-Eynullayeva E, Underhill P, Lane DA, Lip GYH. Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. Eur J Clin Invest. 2021 Nov;51(11):e13679. doi: 10.1111/eci.13679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13679</ArticleId><ArticleId IdType="pmc">PMC8646627</ArticleId><ArticleId IdType="pubmed">34516657</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine. 2021;28:1&#x2013;13. doi: 10.1038/s41591-021-01630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId><ArticleId IdType="pmc">PMC8863574</ArticleId><ArticleId IdType="pubmed">34907393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung-Chen Y. Acute pericarditis due to COVID-19 infection: An underdiagnosed disease? Med Clin (Engl Ed) 2020;155(1):44&#x2013;45. doi: 10.1016/j.medcle.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcle.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7333598</ArticleId><ArticleId IdType="pubmed">32835093</ArticleId></ArticleIdList></Reference><Reference><Citation>Karadeniz H, Yamak BA, &#xd6;zger HS, Sezen&#xf6;z B, Tufan A, Emmi G. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report. Cardiovasc Drugs Ther. 2020;34(6):883&#x2013;885. doi: 10.1007/s10557-020-07044-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07044-3</ArticleId><ArticleId IdType="pmc">PMC7391046</ArticleId><ArticleId IdType="pubmed">32734502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung-Chen Y, Blanco-Alonso S, Ant&#xf3;n-Huguet B, Figueras-L&#xf3;pez C, Ugueto-Rodrigo C. Dolor tor&#xe1;cico persistente tras resoluci&#xf3;n de la enfermedad por coronavirus 2019 (COVID-19) Semergen. 2020;46(Suppl 1):88&#x2013;90. doi: 10.1016/j.semerg.2020.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semerg.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7287471</ArticleId><ArticleId IdType="pubmed">32680679</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraj R, Belkhayat C, Bouchlarhem A, El Aidouni G, Bkiyar H, Housni B. Acute pericarditis revealing COVID-19 infection: Case report. Annals of Medicine and Surgery. 2021 Feb;62:225&#x2013;227. doi: 10.1016/j.amsu.2021.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2021.01.053</ArticleId><ArticleId IdType="pmc">PMC7826081</ArticleId><ArticleId IdType="pubmed">33520219</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschall A, Concepci&#xf3;n Su&#xe1;rez R, Dejuan Bitri&#xe1; C, Fern&#xe1;ndez Pascual MC. Acute pericarditis secondary to COVID-19. Emergencias. 2020;32(3):221&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">32395943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Kumar J, Daly C, Edroos SA. Acute pericarditis as a primary presentation of COVID-19. BMJ Case Reports. 2020;13(8):e237617. doi: 10.1136/bcr-2020-237617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-237617</ArticleId><ArticleId IdType="pmc">PMC7437700</ArticleId><ArticleId IdType="pubmed">32816925</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox K, Prokup JA, Butson K, Jordan K. Acute Effusive Pericarditis: A Late Complication of COVID-19. Cureus. 2020;12(7):e9074. doi: 10.7759/cureus.9074.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.9074</ArticleId><ArticleId IdType="pmc">PMC7348211</ArticleId><ArticleId IdType="pubmed">32656050</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C, Peyko V, Farrell C, Awad-Spirtos J, Adamo M, Scrocco J. Pericardial effusion and cardiac tamponade requiring pericardial window in an otherwise healthy 30-year-old patient with COVID-19: a case report. Journal of Medical Case Reports. 2020;14(1) doi: 10.1186/s13256-020-02467-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02467-w</ArticleId><ArticleId IdType="pmc">PMC7479748</ArticleId><ArticleId IdType="pubmed">32907623</ArticleId></ArticleIdList></Reference><Reference><Citation>Asif T, Kassab K, Iskander F, Alyousef T. Acute Pericarditis and Cardiac Tamponade in a Patient with COVID-19: A Therapeutic Challenge. Eur J Case Rep Intern Med. 2020;7(6):001701. doi: 10.12890/2020_001701.</Citation><ArticleIdList><ArticleId IdType="doi">10.12890/2020_001701</ArticleId><ArticleId IdType="pmc">PMC7279897</ArticleId><ArticleId IdType="pubmed">32523921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandino P&#xe9;rez J, Aubert Girbal L, Caravaca-Font&#xe1;n F, Polanco N, Sevillano Prieto &#xc1;, Andr&#xe9;s A. Pericarditis secundaria a infecci&#xf3;n por COVID-19 en un paciente trasplantado renal. Nefrolog&#xed;a. 2021;41(3):349&#x2013;352. doi: 10.1016/j.nefro.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nefro.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7486811</ArticleId><ArticleId IdType="pubmed">33069495</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoozgar B, Kaushal V, Mubashar U, Sen S, Yousaf S, Yotsuya M. Symptomatic pericardial effusion in the setting of asymptomatic COVID-19 infection: A case report. Medicine (Baltimore) 2020;99(37):e22093. doi: 10.1097/MD.0000000000022093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000022093</ArticleId><ArticleId IdType="pmc">PMC7489591</ArticleId><ArticleId IdType="pubmed">32925751</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetrit M, Xu B, Kwon DH, Ramchand J, Rodriguez RE, Tan CD, et al. Imaging-Guided Therapies for Pericardial Diseases. JACC: Cardiovascular Imaging. 2019;13(6):1422&#x2013;1437. doi: 10.1016/j.jcmg.2019.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2019.08.027</ArticleId><ArticleId IdType="pubmed">31734199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37935015</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>Suppl 3</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[ROC curves: general characteristics and their usefulness in clinical practice].</ArticleTitle><Pagination><StartPage>S497</StartPage><EndPage>S502</EndPage><MedlinePgn>S497-S502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.8319791</ELocationID><Abstract><AbstractText>The use of diagnostic tests to determine the presence or absence of a disease is essential in clinical practice. The results of a diagnostic test may correspond to numerical estimates that require quantitative reference parameters to be transferred to a dichotomous interpretation as normal or abnormal and thus implement actions for the care of a condition or disease. For example, in the diagnosis of anemia it is necessary to define a cut-off point for the hemoglobin variable and create two categories that distinguish the presence or absence of anemia. The method used for this process is the preparation of diagnostic performance curves, better known by their acronym in English as ROC (Receiver Operating Characteristic). The ROC curve is also useful as a prognostic marker, since it allows defining the cut-off point of a quantitative variable that is associated with greater mortality or risk of complications. They have been used in different prognostic markers in COVID-19, such as the neutrophil/lymphocyte ratio and D-dimer, in which cut-off points associated with mortality and/or risk of mechanical ventilation were identified. The ROC curve is used to evaluate the diagnostic performance of a test in isolation, but it can also be used to compare the performance of two or more diagnostic tests and define which one is more accurate. This article describes the basic concepts for the use and interpretation of the ROC curve, the interpretation of an area under the curve (AUC) and the comparison of two or more diagnostic tests.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roy-Garc&#xed;a</LastName><ForeName>Ivonne Anal&#xed;</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0002-1859-3866</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Coordinaci&#xf3;n de Investigaci&#xf3;n en Salud, Centro de Adiestramiento e Investigaci&#xf3;n Cl&#xed;nica. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Escuela Superior de Medicina, Secci&#xf3;n de Posgrado. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes-Manjarrez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3319-7634</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Departamento de Imagenolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Palacios</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9994-4922</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Departamento de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas-Ruiz</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5967-7222</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Coordinaci&#xf3;n de Investigaci&#xf3;n en Salud, Centro de Adiestramiento e Investigaci&#xf3;n Cl&#xed;nica. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Pulido</LastName><ForeName>Andrey Arturo</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-3358-1054</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Escuela Superior de Medicina, Secci&#xf3;n de Posgrado. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Secretar&#xed;a de Salud, Centro Regional de Alta Especialidad, Hospital de Especialidades Pedi&#xe1;tricas. Tuxtla Guti&#xe9;rrez, Chiapas, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Curvas ROC: caracter&#xed;sticas generales y su uso en la pr&#xe1;ctica cl&#xed;nica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="Y">Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="Y">Anemia</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El uso de pruebas diagn&#xf3;sticas para determinar la presencia o ausencia de una enfermedad es esencial en la pr&#xe1;ctica cl&#xed;nica. Los resultados de una prueba diagn&#xf3;stica pueden corresponder a estimaciones num&#xe9;ricas que requieren par&#xe1;metros cuantitativos de referencia para trasladarse a una interpretaci&#xf3;n dicot&#xf3;mica como normal o anormal y as&#xed;, implementar acciones para la atenci&#xf3;n de una condici&#xf3;n o una enfermedad. Por ejemplo, en el diagn&#xf3;stico de anemia es necesario definir un punto de corte para la variable hemoglobina y crear dos categor&#xed;as que distingan la presencia o no de anemia. El m&#xe9;todo utilizado para este proceso es la elaboraci&#xf3;n de curvas de rendimiento diagn&#xf3;stico, mejor conocidas por sus siglas en ingl&#xe9;s como ROC (Receiver Operating Characteristic). La curva ROC adem&#xe1;s es &#xfa;til como marcador pron&#xf3;stico, ya que permite definir el punto de corte de una variable cuantitativa que se asocia a mayor mortalidad o riesgo de complicaciones. Se han usado en distintos marcadores pron&#xf3;sticos en COVID-19, como el &#xed;ndice neutr&#xf3;filos/linfocitos y d&#xed;mero D, en los que se identificaron puntos de corte asociados a mortalidad y/o riesgo de ventilaci&#xf3;n mec&#xe1;nica. La curva ROC se utiliza para evaluar el rendimiento diagn&#xf3;stico de una prueba de forma aislada, pero tambi&#xe9;n se puede usar para comparar el rendimiento de dos o m&#xe1;s pruebas diagn&#xf3;sticas y definir aquella que es m&#xe1;s precisa. En este art&#xed;culo se describen los conceptos b&#xe1;sicos para el uso e interpretaci&#xf3;n de la curva ROC, la interpretaci&#xf3;n de un &#xe1;rea bajo la curva (ABC) y la comparaci&#xf3;n de dos o m&#xe1;s pruebas diagn&#xf3;sticas.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Area Under Curve</Keyword><Keyword MajorTopicYN="N">Curva ROC</Keyword><Keyword MajorTopicYN="N">Diagnostic Techniques and Procedures</Keyword><Keyword MajorTopicYN="N">Estad&#xed;stica</Keyword><Keyword MajorTopicYN="N">ROC Curve</Keyword><Keyword MajorTopicYN="N">Statistics</Keyword><Keyword MajorTopicYN="N">T&#xe9;cnicas y Procedimientos Diagn&#xf3;sticos</Keyword><Keyword MajorTopicYN="N">&#xc1;rea Bajo la Curva</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37935015</ArticleId><ArticleId IdType="pmc">PMC10754459</ArticleId><ArticleId IdType="doi">10.5281/zenodo.8319791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talavera JO, Wacher-Rodarte NH, Rivas-Ruiz R. Clinical research II. Studying the process (the diagnosis test) Rev Med Inst Mex Seguro Soc. 2011;49(2):163&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703143</ArticleId></ArticleIdList></Reference><Reference><Citation>Obuchowski NA. An ROC-type measure of diagnostic accuracy when the gold standard is continuous-scale. Stat Med. 2006;25(3):481&#x2013;493. doi: 10.1002/sim.2228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2228</ArticleId><ArticleId IdType="pubmed">16287217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315&#x2013;1316. doi: 10.1097/JTO.0b013e3181ec173d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e3181ec173d</ArticleId><ArticleId IdType="pubmed">20736804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Cao W, Li Q, Shen H, Liu C, Deng J, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;10(6):25776. doi: 10.1038/srep25776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25776</ArticleId><ArticleId IdType="pmc">PMC4861967</ArticleId><ArticleId IdType="pubmed">27161545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartziokas K, Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Med Clin (Barc) 2021;156(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832973</ArticleId><ArticleId IdType="pubmed">33521309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennouar S, Bachir Cherif A, Kessira A, Hamel H, Boudahdir A, Bouamra A, Bennouar D, Abdi S. Usefulness of biological markers in the early prediction of corona virus disease-2019 severity. Scand J Clin Lab Invest. 2020;80(8):611&#x2013;618. doi: 10.1080/00365513.2020.1821396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2020.1821396</ArticleId><ArticleId IdType="pubmed">32945705</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25&#x2013;36. doi: 10.4097/kja.21209.</Citation><ArticleIdList><ArticleId IdType="doi">10.4097/kja.21209</ArticleId><ArticleId IdType="pmc">PMC8831439</ArticleId><ArticleId IdType="pubmed">35124947</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Bai T, Yang B, Sun L. The diagnostic value of D-dimer in acute aortic dissection: a meta-analysis. J Cardiothorac Surg. 2021;16(1):343. doi: 10.1186/s13019-021-01726-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-021-01726-1</ArticleId><ArticleId IdType="pmc">PMC8627055</ArticleId><ArticleId IdType="pubmed">34838062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wussler D, Kozhuharov N, Tavares-Oliveira M, Bossa A, Sabti Z, Nowak A, et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem. 2019;65(12):1532&#x2013;1542. doi: 10.1373/clinchem.2019.306787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2019.306787</ArticleId><ArticleId IdType="pubmed">31615771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Lim JY, Huang W. Statistical considerations for repeatability and reproducibility of quantitative imaging biomarkers. BJR Open. 2022;4(1):20210083. doi: 10.1259/bjro.20210083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1259/bjro.20210083</ArticleId><ArticleId IdType="pmc">PMC9667479</ArticleId><ArticleId IdType="pubmed">36452056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Camblor P, Pardo-Fern&#xe1;ndez JC. The Youden Index in the Generalized Receiver Operating Characteristic Curve Context. Int J Biostat. 2019;15(1):/j/ijb.2019. doi: 10.1515/ijb-2018-0060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/ijb-2018-0060</ArticleId><ArticleId IdType="pubmed">30943172</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguglia A, Natale A, Fusar-Poli L, Gnecco GB, Lechiara A, Marino M, et al. C-Reactive Protein as a Potential Peripheral Biomarker for High-Lethality Suicide Attempts. Life (Basel) 2022;12(10):1557. doi: 10.3390/life12101557.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12101557</ArticleId><ArticleId IdType="pmc">PMC9605506</ArticleId><ArticleId IdType="pubmed">36294992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Du Z, Shen S, Zhang B, Yang H, Li X, et al. Identification and Validation of a Novel Clinical Signature to Predict the Prognosis in Confirmed Coronavirus Disease 2019 Patients. Clin Infect Dis. 2020;71(12):3154&#x2013;3162. doi: 10.1093/cid/ciaa793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa793</ArticleId><ArticleId IdType="pmc">PMC7337707</ArticleId><ArticleId IdType="pubmed">32556293</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist&#xe1;n-Mart&#xed;nez PD, Doubova SV, Sauceda-Valenzuela AL. Calidad de atenci&#xf3;n en pacientes con c&#xe1;ncer de pr&#xf3;stata atendidos en M&#xe9;xico. Rev Med Inst Mex Seguro Soc. 2022;60(3):275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10395871</ArticleId><ArticleId IdType="pubmed">35759755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Xue J, Liu Z, Dai W, Xu H, Zhou Q, et al. The Lactate/Albumin Ratio Predicts Mortality in Critically Ill Patients with Acute Kidney Injury: An Observational Multicenter Study on the eICU Database. Int J Gen Med. 2021;14:10511&#x2013;10525. doi: 10.2147/IJGM.S339767.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S339767</ArticleId><ArticleId IdType="pmc">PMC8722580</ArticleId><ArticleId IdType="pubmed">35002307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Park E, Chang YC. Comparison of Paired ROC Curves through a Two-Stage Test. J Biopharm Stat. 2015;25(5):881&#x2013;902. doi: 10.1080/10543406.2014.920874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10543406.2014.920874</ArticleId><ArticleId IdType="pubmed">24905904</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Li Z, Yao G, Wei S, Li L, Wu H. Framework for feature selection of predicting the diagnosis and prognosis of necrotizing enterocolitis. PLoS One. 2022;17(8):e0273383. doi: 10.1371/journal.pone.0273383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273383</ArticleId><ArticleId IdType="pmc">PMC9390903</ArticleId><ArticleId IdType="pubmed">35984833</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Mu F, Gao K, Yan C, Chen G, Guo C. Value of abdominal ultrasonography in predicting intestinal resection for premature infants with necrotizing enterocolitis. BMC Gastroenterol. 2022;22(1):524. doi: 10.1186/s12876-022-02607-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-022-02607-0</ArticleId><ArticleId IdType="pmc">PMC9758908</ArticleId><ArticleId IdType="pubmed">36526960</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Li D, Liu X, Zhang B, Zang Y, Ma J, et al. Elevated Serum Procalcitonin to Predict Severity and Prognosis of Extensive Burns. J Invest Surg. 2022;35(7):1510&#x2013;1518. doi: 10.1080/08941939.2022.2073489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08941939.2022.2073489</ArticleId><ArticleId IdType="pubmed">35574977</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker M, van Herk W, El Helou S, Dutta S, Schuerman FABA, van den Tooren-de Groot RK, et al. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study. Clin Infect Dis. 2021;73(2):e383&#x2013;e390. doi: 10.1093/cid/ciaa876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa876</ArticleId><ArticleId IdType="pubmed">32881994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37934671</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>Suppl 3</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Characteristics of patients with systemic sclerosis who develop interstitial lung disease].</ArticleTitle><Pagination><StartPage>S363</StartPage><EndPage>S371</EndPage><MedlinePgn>S363-S371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.8383951</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Systemic sclerosis associated-interstitial lung disease (SSc-ILD) show a high mortality. The factors associated SSc-ILD have shown variability in different populations. There are few studies in Mexican mestizos.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To analyze the epidemiological, clinical and paraclinical factors associated with SSc-ILD.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Cross-sectional study, where patients &gt; 18 years of age with a diagnosis of SSc according to EULAR/ACR 2013 criteria and diagnosis of ILD by forced vital capacity (FVC) &lt; 70% and &gt; 5% of affected lung area on tomography were included. The strength of association of the factors for ILD was measured by odds ratio (OR) with 95% confidence intervals (95% CI). The significant variables were analyzed by multiple logistic regression with adjustment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 80 patients with SSc, 38 (47.5%) had ILD. Risk factors such as smoking, higher activity index, lower FVC, anti-topoisomerase I antibodies, and protective factors such as a limited SSc, early capillaroscopic pattern, and anti-centromere antibodies (ACA) were associated with ILD. In the multivariate analysis, a higher activity index with OR 4.17, (95% CI 2.01-8.65) persisted as a risk factor, while ACA with OR 0.17, (95% CI 0.03-0.85) persisted as a protective factor associated with SSc-ILD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A higher index of activity and ACA persisted as factors associated with SSc-ILD.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fajardo-Hermosillo</LastName><ForeName>Luis Daniel</ForeName><Initials>LD</Initials><Identifier Source="ORCID">0000-0002-8901-8383</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional de Occidente, Hospital de Especialidades, Servicio de Reumatolog&#xed;a. Guadalajara, Jalisco, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocampo-Torres</LastName><ForeName>Mario C&#xe9;sar</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-5414-0346</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Reumatolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Silverio</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8998-1196</Identifier><AffiliationInfo><Affiliation>Instituto Polit&#xe9;cnico Nacional, Escuela Superior de Medicina. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas de los pacientes con esclerosis sist&#xe9;mica que desarrollan enfermedad pulmonar intersticial.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">la enfermedad pulmonar intersticial (EPI) est&#xe1; relacionada a una mayor mortalidad en esclerosis sist&#xe9;mica (ES). Los factores asociados a su presentaci&#xf3;n han mostrado variabilidad en diferentes poblaciones. Pocos estudios se han realizado en mestizos mexicanos.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">analizar los factores cl&#xed;nicos y paracl&#xed;nicos asociados a EPI en pacientes con ES.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio retrospectivo de casos y controles en el que se incluyeron pacientes &gt; 18 a&#xf1;os con diagn&#xf3;stico de ES, seg&#xfa;n criterios EULAR/ACR 2013 y EPI por capacidad vital forzada (CVF) &lt; 70% y &gt; 5% de &#xe1;rea pulmonar efectada en tomograf&#xed;a. La fuerza de asociaci&#xf3;n de los factores para EPI se midi&#xf3; por raz&#xf3;n de momios (RM) con intervalos de confianza del 95% (IC95%). Las variables significativas se analizaron por regresi&#xf3;n log&#xed;stica m&#xfa;ltiple con ajuste.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">de los 80 pacientes con ES, 38 (47.5%) ten&#xed;an EPI. Factores de riesgo como tabaquismo, mayor &#xed;ndice de actividad, menor CVF, anticuerpos antitopoisomerasa I y factores protectores como variedad limitada de ES, patr&#xf3;n capilarosc&#xf3;pico temprano y anticuerpos anticentr&#xf3;mero estuvieron asociados a EPI. En el an&#xe1;lisis multivariado un mayor &#xed;ndice de actividad con RM 4.17, (IC95%: 2.01-8.65) persisti&#xf3; como un factor de riesgo; en cambio, los anticuerpos anticentr&#xf3;mero con RM 0.17, (IC95%: 0.03-0.85) persistieron como un factor protector asociado a EPI.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">un mayor &#xed;ndice de actividad y la presencia anticuerpos anticentr&#xf3;mero persistieron como factores asociados a la presencia de EPI en ES.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticentromere Antibodies</Keyword><Keyword MajorTopicYN="N">Anticuerpos Anticentr&#xf3;mero</Keyword><Keyword MajorTopicYN="N">Cross-Sectional Studies</Keyword><Keyword MajorTopicYN="N">Enfermedades Pulmonares Intersticiales</Keyword><Keyword MajorTopicYN="N">Esclerodermia Sist&#xe9;mica</Keyword><Keyword MajorTopicYN="N">Estudios Transversales</Keyword><Keyword MajorTopicYN="N">Factores de Riesgo</Keyword><Keyword MajorTopicYN="N">Lung Diseases, Interstitial</Keyword><Keyword MajorTopicYN="N">Risk Factors</Keyword><Keyword MajorTopicYN="N">Scleroderma, Systemic</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37934671</ArticleId><ArticleId IdType="pmc">PMC10730132</ArticleId><ArticleId IdType="doi">10.5281/zenodo.8383951</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304&#x2013;320. doi: 10.1016/S2213-2600(19)30480-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(19)30480-1</ArticleId><ArticleId IdType="pubmed">32113575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, et al. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respir Res. 2020;21(1):197. doi: 10.1186/s12931-020-01459-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01459-0</ArticleId><ArticleId IdType="pmc">PMC7379834</ArticleId><ArticleId IdType="pubmed">32703199</ArticleId></ArticleIdList></Reference><Reference><Citation>Molberg &#xd8;, Hoffmann-Vold AM. Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis. Curr Opin Rheumatol. 2016;28(6):613&#x2013;618. doi: 10.1097/BOR.0000000000000323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000323</ArticleId><ArticleId IdType="pubmed">27387267</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo H, Hino T, Han J, Franks TJ, Im Y, Hatabu H, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. Eur J Radiol Open. 2020;8 doi: 10.1016/j.ejro.2020.100311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejro.2020.100311</ArticleId><ArticleId IdType="pmc">PMC7750149</ArticleId><ArticleId IdType="pubmed">33364263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol. 2016;28(3):236&#x2013;245. doi: 10.1097/BOR.0000000000000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000270</ArticleId><ArticleId IdType="pmc">PMC4826478</ArticleId><ArticleId IdType="pubmed">27027811</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248&#x2013;1254. doi: 10.1164/rccm.200706-877OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200706-877OC</ArticleId><ArticleId IdType="pubmed">18369202</ArticleId></ArticleIdList></Reference><Reference><Citation>Amjadi SS, Roofeh D, Namas R, Khanna D. Management of systemic sclerosis-associated interstitial lung disease in the current era. Int J Rheum Dis. 2020;23(2):137&#x2013;139. doi: 10.1111/1756-185X.13799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13799</ArticleId><ArticleId IdType="pmc">PMC7083212</ArticleId><ArticleId IdType="pubmed">32043307</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire M, Rivera A, Sope&#xf1;a B, Tolosa Vilella C, Guill&#xe9;n-Del Castillo A, Colunga Arg&#xfc;elles D, et al. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. Clin Exp Rheumatol. 2017;35(Suppl 106):89&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980905</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann ER, Steen V, Li N, Roth MD, Clements PJ, Furst DE, et al. Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. ACR Open Rheumatol. 2021;3(1):8&#x2013;16. doi: 10.1002/acr2.11206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11206</ArticleId><ArticleId IdType="pmc">PMC7811695</ArticleId><ArticleId IdType="pubmed">33277978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballerie A, Cavalin C, Lederlin M, Nicolas A, Garlant&#xe9;zec R, Jouneau S, et al. Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis. Semin Arthritis Rheum. 2020;50(5):949&#x2013;956. doi: 10.1016/j.semarthrit.2020.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.08.014</ArticleId><ArticleId IdType="pubmed">32906030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihtyanova SI, Denton CP. Pathogenesis of systemic sclerosis associated interstitial lung disease. Journal of Scleroderma and Related Disorders. 2020;5(2_suppl):6&#x2013;16. doi: 10.1177/2397198320903867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2397198320903867</ArticleId><ArticleId IdType="pmc">PMC8922569</ArticleId><ArticleId IdType="pubmed">35382227</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett-Smith EC, Fonseca C, et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis. Arthritis Rheumatol. 2020;72(3):465&#x2013;476. doi: 10.1002/art.41153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41153</ArticleId><ArticleId IdType="pubmed">31682743</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Cano D, Ortego-Centeno N, Callejas JL, Fonollosa Pl&#xe1; V, R&#xed;os-Fern&#xe1;ndez R, Tolosa-Vilella C, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. 2018;38(3):363&#x2013;374. doi: 10.1007/s00296-017-3916-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3916-x</ArticleId><ArticleId IdType="pubmed">29322341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashmore P, Tikly M, Wong M, Ickinger C. Interstitial lung disease in South Africans with systemic sclerosis. Rheumatol Int. 2018;38(4):657&#x2013;662. doi: 10.1007/s00296-017-3893-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3893-0</ArticleId><ArticleId IdType="pubmed">29185086</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nu&#xf1;ez-Alvarez CA, Torrico-Lavayen R, Garc&#xed;a-Hern&#xe1;ndez JL, et al. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity. 2011;44(7):576&#x2013;584. doi: 10.3109/08916934.2011.592886.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2011.592886</ArticleId><ArticleId IdType="pubmed">21875377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Lopez L, Rocha-Mu&#xf1;oz AD, Olivas-Flores EM, Garcia-Gonzalez A, Peguero-G&#xf3;mez AR, Flores-Navarro J, et al. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis. Arch Bronconeumol. 2015;51(9):440. doi: 10.1016/j.arbres.2014.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbres.2014.06.018</ArticleId><ArticleId IdType="pubmed">25301411</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270&#x2013;276. doi: 10.1136/annrheumdis-2016-209768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209768</ArticleId><ArticleId IdType="pubmed">27621285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross L, Baron M, Nikpour M. The challenges and controversies of measuring disease activity in systemic sclerosis. J Scleroderma Relat Disord. 2018;3(2):115&#x2013;121. doi: 10.1177/2397198318765061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2397198318765061</ArticleId><ArticleId IdType="pmc">PMC8892866</ArticleId><ArticleId IdType="pubmed">35382236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578&#x2013;587. doi: 10.1038/nrrheum.2010.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.104</ArticleId><ArticleId IdType="pubmed">20703220</ArticleId></ArticleIdList></Reference><Reference><Citation>Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S42&#x2013;S46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889222</ArticleId></ArticleIdList></Reference><Reference><Citation>Matucci-Cerinic M, D'Angelo S, Denton CP, Vlachoyiannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S19&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambataro D, Sambataro G, Pignataro F, Maglione W, Malatino L, Vancheri C, et al. Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. Diagnostics (Basel) 2020;10(4):225. doi: 10.3390/diagnostics10040225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10040225</ArticleId><ArticleId IdType="pmc">PMC7235772</ArticleId><ArticleId IdType="pubmed">32316226</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock CJW, Renzoni EA. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet. 2018;26(6):765&#x2013;777. doi: 10.1038/s41431-018-0104-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0104-8</ArticleId><ArticleId IdType="pmc">PMC5974020</ArticleId><ArticleId IdType="pubmed">29476163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonhomme O, Andr&#xe9; B, Gester F, de Seny D, Moermans C, Struman I, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford) 2019;58(9):1534&#x2013;1546. doi: 10.1093/rheumatology/kez230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez230</ArticleId><ArticleId IdType="pmc">PMC6736409</ArticleId><ArticleId IdType="pubmed">31292645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashiri SY, Nishino A, Igawa T, Takatani A, Shimizu T, Umeda M, et al. Prediction of organ involvement in systemic sclerosis by serum biomarkers and peripheral endothelial function. Clin Exp Rheumatol. 2018;36(Suppl 113):102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">29652651</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>